PLoS One. 2022 Mar 11;17(3):e0265332. doi: 10.1371/journal.pone.0265332. eCollection 2022.
ABSTRACT
BACKGROUND: The coexistence of Graves' disease with thyroid cancer is well-known and total thyroidectomy is recommended in such cases. However, Graves' disease might be dormant at the time of surgery and diagnosed after lobectomy for thyroid cancer.
METHODS: We assessed the incidence and clinicopathological characteristic of newly developed Graves' disease after lobectomy for t hyroid cancer between 2010 and 2019.
RESULTS: In all, 11043 patients underwent lobectomy for thyroid cancer during the study period, and 26 (0.2%) were diagnosed with Graves' disease during follow-up. The median age was 43.8 years, 88.5% were female, and all were euthyroid before surgery. The median time from lobectomy to the diagnosis of Graves' disease was 3.3 years. Half of the patients were diagnosed based on thyroid function tests during routine follow-up, and others were diagnosed due to symptoms of thyrotoxicosis. Among patients who had checked preoperative thyroid autoantibodies, 61.1% showed positivity. Twenty-one (80.8%), and 2 (7.7%) patients received antithyroid drugs and radioactive iodine therapy, respectively, and 3 (11.5%) underwent completion thyroidectomy.
CONCLUSION: Although rare, Graves' disease can occur in the remnant thyroid after lobectomy. Such patients are more likely to have autoantibodies. An appropriate workup is required when hyperthyroidis m is found during the follow-up of patients after lobectomy.
PMID:35275968 | PMC:PMC8916678 | DOI:10.1371/journal.pone.0265332
No comments:
Post a Comment